nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Artesunate versus quinine: the controlled trials watershed
|
Keating, Conrad |
|
|
401 |
10385 |
p. 1329-1331 |
artikel |
2 |
Assessing COVID-19 pandemic policies and behaviours and their economic and educational trade-offs across US states from Jan 1, 2020, to July 31, 2022: an observational analysis
|
Bollyky, Thomas J |
|
|
401 |
10385 |
p. 1341-1360 |
artikel |
3 |
Barbara C Staggers
|
Green, Andrew |
|
|
401 |
10385 |
p. 1334 |
artikel |
4 |
Clinical aspects of snakebite envenoming and its treatment in low-resource settings
|
Warrell, David A |
|
|
401 |
10385 |
p. 1382-1398 |
artikel |
5 |
Decentralised elements in clinical trials: recommendations from the European Medicines Regulatory Network
|
Al, Monique |
|
|
401 |
10385 |
p. 1339 |
artikel |
6 |
Department of Error
|
|
|
|
401 |
10385 |
p. 1340 |
artikel |
7 |
Drug developers caution against US mifepristone ban
|
Jaffe, Susan |
|
|
401 |
10385 |
p. 1325-1326 |
artikel |
8 |
Endovascular treatment versus no endovascular treatment after 6–24 h in patients with ischaemic stroke and collateral flow on CT angiography (MR CLEAN-LATE) in the Netherlands: a multicentre, open-label, blinded-endpoint, randomised, controlled, phase 3 trial
|
Olthuis, Susanne G H |
|
|
401 |
10385 |
p. 1371-1380 |
artikel |
9 |
Evaluating the impact of alcohol minimum unit pricing on deaths and hospitalisations in Scotland: a controlled interrupted time series study
|
Wyper, Grant M A |
|
|
401 |
10385 |
p. 1361-1370 |
artikel |
10 |
Even more benefit with endovascular treatment for patients with acute ischaemic stroke: MR CLEAN-LATE
|
Wardlaw, Joanna M |
|
|
401 |
10385 |
p. 1317-1319 |
artikel |
11 |
Fluid retention and heart failure in the PRECISION trial
|
Kohan, Donald E |
|
|
401 |
10385 |
p. 1335 |
artikel |
12 |
Fluid retention and heart failure in the PRECISION trial – Authors' reply
|
Schlaich, Markus P |
|
|
401 |
10385 |
p. 1335-1336 |
artikel |
13 |
Improving access to global cancer services
|
Mahajan, Arnav |
|
|
401 |
10385 |
p. 1338-1339 |
artikel |
14 |
Key questions regarding the SYMPLICITY HTN-3 trial
|
Tanemoto, Masayuki |
|
|
401 |
10385 |
p. 1337 |
artikel |
15 |
Key questions regarding the SYMPLICITY HTN-3 trial
|
Kjeldsen, Sverre E |
|
|
401 |
10385 |
p. 1336-1337 |
artikel |
16 |
Key questions regarding the SYMPLICITY HTN-3 trial – Authors' reply
|
Bhatt, Deepak L |
|
|
401 |
10385 |
p. 1337-1338 |
artikel |
17 |
Lessons learned from COVID-19 to stop future pandemics
|
Cueni, Thomas |
|
|
401 |
10385 |
p. 1340 |
artikel |
18 |
Minimum unit pricing for alcohol targets harms experienced by people in lower socioeconomic groups in Scotland
|
Callinan, Sarah |
|
|
401 |
10385 |
p. 1315-1317 |
artikel |
19 |
Offline: The UK COVID-19 Inquiry—be patient, but don’t wait
|
Horton, Richard |
|
|
401 |
10385 |
p. 1324 |
artikel |
20 |
Promote global solidarity to advance health-system resilience: proposals for the G7 meetings in Japan
|
|
|
|
401 |
10385 |
p. 1319-1321 |
artikel |
21 |
Racism, xenophobia, and discrimination: data disaggregation is a complex but crucial step to improving child health
|
Devakumar, Delan |
|
|
401 |
10385 |
p. 1321-1323 |
artikel |
22 |
Rare diseases: democratising genetic testing in LMICs
|
Núñez-Samudio, Virginia |
|
|
401 |
10385 |
p. 1339-1340 |
artikel |
23 |
Routine immunisations: reversing the decline
|
The Lancet, |
|
|
401 |
10385 |
p. 1313 |
artikel |
24 |
State-to-state differences in US COVID-19 outcomes: searching for explanations
|
Lurie, Nicole |
|
|
401 |
10385 |
p. 1314-1315 |
artikel |
25 |
Transcriptomics aids differentiation of IL-23 overactivity in a patient with atypical skin and joint disease
|
Hakimi, Marwa |
|
|
401 |
10385 |
p. 1381 |
artikel |
26 |
Uganda's “anti-homosexuality” bill already affecting care
|
Jerving, Sara |
|
|
401 |
10385 |
p. 1327-1328 |
artikel |
27 |
Visual representation, medicine, and imperialism
|
Chatterjee, Apurba |
|
|
401 |
10385 |
p. 1332-1333 |
artikel |